Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors
This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for cancer patients can achieve a blockbuster status. Within cancer therapeutics, immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures in 317 pages.
Key Questions Answered in this Report
· What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2020?
· What is the global market for cancer immunotherapeutics by geography, through 2020
· What is the global market for cancer immunotherapeutics by indication, through 2020?
· What is the global market for MAbs by type such as naked MAbs and ADCs, through 2020?
· What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda?
· What is the global market for cancer vaccines?
· What is the global market for cytokines in cancer immunotherapy?
· The projected market values for Nivolumab, RG7446, DCVax-L, MEDI4736 ?
· What immunotherapies were approved between 1986 and 2016?
· What monoclonal antibodies (MAbs) were approved by the FDA to treat different types of cancers?
By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors)
By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)
A comprehensive account of company product portfolios are provided for 79 Cancer Immunotherapy pharma and biotech companies including:
Biogen Idec Inc.x
Bristol-Myers Squibb Co.
Cellerant Therapeutics Inc.
Eli Lilly and Co.
EMD Serono Inc.
Janssen Biotech Inc.
Juno Therapeutics Inc.
Merck & Co., Inc.
Oxford BioTherapeutics Ltd.
Progenics Pharmaceuticals Inc.
Roche Holdings Inc.
Seattle Genetics Inc.
Sorrento Therapeutics Inc
Prior to the launching of Yervoy, the five-year survival rate for patients with early stage melanoma was 98%; but the five-year survival rate for late-stage melanoma was just 16%. Yervoy has been reported to have a survival rate of 25% when tested alone. When tested as part of a combination therapy treatment with Bristol’s nivolumab, the two-year survival rates rose to 88% for patients with late-stage cancer. Increase in patient survival rates brought about by cancer immunotherapy treatment is similar to that seen when bone marrow transplantation changed our conception on how blood cancer was treated.
Table of Content: Key Points
1.0 Executive Summary 21
1.1 Objectives of Report 22
1.2 Key Questions Answered in this Report 22
1.3 Data Sources and Methodology 23
2.0 Cancer Immunotherapy: An Overview 24
2.1 Human Immune System 24
2.1.1 Components of Human Immune System 25
2.2 Types of Cancer Immunotherapy 26
2.3 Monoclonal Antibodies (Mabs) to Treat Cancer 27
2.3.1 Most Frequently Targeted Antigens by MAbs 27
2.4 Types of Monoclonal Antibodies (MAbs) 29
2.4.1 Naked MAbs 29
2.4.2 Conjugated Monoclonal Antibodies 30
22.214.171.124 Components of an Antibody Drug Conjugate (ADC) 30
126.96.36.199 Mechanism of Action of Antibody Drug Conjugate (ADC) 31
188.8.131.52 The Cytotoxic Wareheads used in ADCs 31
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: